SequelSEC

AbCellera Biologics Inc. ABCL

Pharmaceutical Preparations · CIK 0001703057 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$75.13M
Fiscal year ended 2025-12-31
Operating income
-$217.10M
Fiscal year ended 2025-12-31
Free cash flow
-$174.07M
Fiscal year ended 2025-12-31

AbCellera Biologics Inc. (ABCL) reported revenue of $75.13M and net income of -$146.41M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from AbCellera Biologics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

AbCellera Biologics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$75.13M$28.83M$38.02M$485.42M$375.20M$233.16M$11.61M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$217.10M-$314.77M-$237.21M$216.51M$204.41M$156.03M-$4.12M
Net income-$146.41M-$162.86M-$146.40M$158.52M$153.46M$118.92M-$2.21M
Research & development$186.83M$167.26M$175.66M$107.88M$62.06M$29.39M$10.11M
Weighted-average diluted sharesshares 298.71Mshares 294.33Mshares 289.17Mshares 314.83Mshares 318.29Mshares 263.13Mshares 151.33M
Pretax income-$177.60M-$200.40M-$174.03M$239.10M$219.15M$157.83M-$2.21M
Income tax expense-$31.18M-$37.54M-$27.63M$80.58M$65.68M$38.92MUnavailable
Diluted EPS$-0.49$-0.55$-0.51$0.50$0.48$0.45$-0.01
Selling, general & administrativeUnavailableUnavailableUnavailable$66.76M$48.76M$15.75M$4.01M
General & administrative$83.23M$85.49M$75.18M$55.48M$41.85M$11.91M$2.75M
Selling & marketingUnavailable$12.78M$14.18M$11.27M$6.91M$3.84M$1.26M

Balance

AbCellera Biologics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$128.51M$156.32M$133.32M$386.54M$476.14M$594.12MUnavailable
Total assets$1.36B$1.36B$1.49B$1.54B$1.32B$1.01BUnavailable
Current assets$728.23M$751.37M$871.98M$1.03B$929.80M$813.32MUnavailable
Total liabilities$390.05M$304.47M$335.78M$307.63M$292.84M$175.03MUnavailable
Current liabilities$64.31M$76.61M$119.01M$118.32M$120.68M$103.49MUnavailable
Total equity incl. NCI$966.90M$1.06B$1.15B$1.23B$1.03B$830.51M$10.25M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$6.34M$0UnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$39.41M$31.98M$0UnavailableUnavailable$903.00KUnavailable
Goodwill$47.81M$47.81M$47.81M$47.81M$47.81M$31.50MUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

AbCellera Biologics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$131.30M-$108.56M-$43.88M$277.36M$244.58M$22.69M$2.69M
Capital expenditures$42.77M$78.40M$76.95M$70.66M$58.45M$9.67M$4.00M
Investing cash flow$87.75M$121.41M-$221.11M-$352.62M-$332.25M-$119.78M-$5.78M
Financing cash flow$14.08M$12.77M$10.36M-$1.63M-$3.89M$683.65M$195.00K
Net change in cash-$28.37M$23.00M-$254.04M-$86.49M-$92.97M$586.56M-$2.89M
Stock-based compensation$55.79M$67.58M$64.18M$49.48M$30.65M$8.40M$890.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable$24.40M$27.84M$14.45M$4.84M$1.60M

Derived

AbCellera Biologics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$174.07M-$186.95M-$120.82M$206.70M$186.13M$13.02M-$1.30M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-289.0%-1091.7%-623.8%44.6%54.5%66.9%-35.5%
FCF margin-231.7%-648.4%-317.7%42.6%49.6%5.6%-11.2%
SBC / revenue74.3%234.4%168.8%10.2%8.2%3.6%7.7%
Current ratio11.32x9.81x7.33x8.67x7.70x7.86xUnavailable
Revenue YoY growth160.6%-24.2%-92.2%29.4%60.9%1907.9%Unavailable
Net margin-194.9%-564.8%-385.0%32.7%40.9%51.0%-19.0%
R&D / revenue248.7%580.1%462.0%22.2%16.5%12.6%87.1%
CapEx / revenue56.9%271.9%202.4%14.6%15.6%4.1%34.4%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable33.7%30.0%24.7%Unavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ABCL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV ACTU

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.